Breakthrough drug trial aims to halt rare kidney disease progression

NCT ID NCT04817618

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing whether the drug iptacopan can help control a rare kidney disease called C3G. About 98 patients aged 12-60 will receive either the drug or a placebo for 6-12 months, along with their standard care. Researchers will check if the drug reduces protein in urine, improves kidney function, and is safe.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

Albany Medical Center
WITHDRAWN

Albany, New York, 12208, United States
Baylor Scott and White Research
WITHDRAWN

Temple, Texas, 76502, United States
Brigham and Womens Hosp Harvard Med School
WITHDRAWN

Boston, Massachusetts, 02115, United States
Childrens Hospital Colorado
RECRUITING

Aurora, Colorado, 80045, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Col Uni Med Center New York Presby
COMPLETED

New York, New York, 10032, United States
Georgia Nephrology Research Inst
ACTIVE_NOT_RECRUITING

Lawrenceville, Georgia, 30046, United States
Hackensack Uni Medical Center
RECRUITING

Hackensack, New Jersey, 07601, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
IN University School of Med
RECRUITING

Indianapolis, Indiana, 46202-5111, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Johns Hopkins Hospital
WITHDRAWN

Baltimore, Maryland, 21287, United States
Nicklaus Childrens Hospital
RECRUITING

Miami, Florida, 33155, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Novartis Investigative Site
WITHDRAWN

Córdoba, Córdoba Province, 5000, Argentina
Novartis Investigative Site
COMPLETED

Buenos Aires, W3400ABH, Argentina
Novartis Investigative Site
WITHDRAWN

CABA, C1181ACH, Argentina
Novartis Investigative Site
WITHDRAWN

Edegem, 2650, Belgium
Novartis Investigative Site
WITHDRAWN

Leuven, 3000, Belgium
Novartis Investigative Site
RECRUITING

Belo Horizonte, Minas Gerais, 30150-221, Brazil
Novartis Investigative Site
RECRUITING

Recife, Pernambuco, 50740-900, Brazil
Novartis Investigative Site
RECRUITING

Passo Fundo, Rio Grande do Sul, 99010-260, Brazil
Novartis Investigative Site
WITHDRAWN

Joinville, Santa Catarina, 893227-680, Brazil
Novartis Investigative Site
WITHDRAWN

Santo André, São Paulo, 09090-790, Brazil
Novartis Investigative Site
RECRUITING

São Paulo, São Paulo, 04038-002, Brazil
Novartis Investigative Site
WITHDRAWN

São Paulo, São Paulo, 05403 000, Brazil
Novartis Investigative Site
RECRUITING

Salvador, 40323-010, Brazil
Novartis Investigative Site
COMPLETED

London, Ontario, N6A 5W9, Canada
Novartis Investigative Site
WITHDRAWN

Toronto, Ontario, M5G 2C4, Canada
Novartis Investigative Site
RECRUITING

Montreal, Quebec, H3T 1C5, Canada
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Guangzhou, Guangdong, 510030, China
Novartis Investigative Site
WITHDRAWN

Wuhan, Hubei, 430022, China
Novartis Investigative Site
RECRUITING

Beijing, 100034, China
Novartis Investigative Site
RECRUITING

Beijing, 100730, China
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Shanghai, 200040, China
Novartis Investigative Site
COMPLETED

Prague, 128 08, Czechia
Novartis Investigative Site
COMPLETED

Lille, 59037, France
Novartis Investigative Site
WITHDRAWN

Marseille, 13005, France
Novartis Investigative Site
WITHDRAWN

Montpellier, 34295, France
Novartis Investigative Site
COMPLETED

Paris, 75015, France
Novartis Investigative Site
WITHDRAWN

Paris, 75019, France
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Cologne, North Rhine-Westphalia, 50937, Germany
Novartis Investigative Site
WITHDRAWN

Aachen, 52074, Germany
Novartis Investigative Site
COMPLETED

Erlangen, 91054, Germany
Novartis Investigative Site
COMPLETED

Essen, 45147, Germany
Novartis Investigative Site
RECRUITING

Hamburg, 20246, Germany
Novartis Investigative Site
WITHDRAWN

Hanover, 30625, Germany
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Heidelberg, 69120, Germany
Novartis Investigative Site
COMPLETED

Mainz, 55131, Germany
Novartis Investigative Site
WITHDRAWN

Athens, 115 27, Greece
Novartis Investigative Site
COMPLETED

Heraklion Crete., 715 00, Greece
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Thessaloniki, 546 42, Greece
Novartis Investigative Site
WITHDRAWN

Thessaloniki, 546 42, Greece
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

New Delhi, National Capital Territory of Delhi, 110017, India
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

New Delhi, National Capital Territory of Delhi, 110029, India
Novartis Investigative Site
WITHDRAWN

Hyderabad, Telangana, 500058, India
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Lucknow, Uttar Pradesh, 226014, India
Novartis Investigative Site
WITHDRAWN

Dehradun, Uttarakhand, 248001, India
Novartis Investigative Site
COMPLETED

Petah Tikva, 4920235, Israel
Novartis Investigative Site
COMPLETED

Petah Tikva, 4941492, Israel
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Ranica, BG, 24020, Italy
Novartis Investigative Site
WITHDRAWN

Milan, MI, 20122, Italy
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Roma, RM, 00165, Italy
Novartis Investigative Site
COMPLETED

Nagoya, Aichi-ken, 4668560, Japan
Novartis Investigative Site
COMPLETED

Asahikawa, Hokkaido, 0788510, Japan
Novartis Investigative Site
COMPLETED

Sapporo, Hokkaido, 0608543, Japan
Novartis Investigative Site
COMPLETED

Takatsuki, Osaka, 569 1192, Japan
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Ohtsu, Shiga, 5202192, Japan
Novartis Investigative Site
COMPLETED

Niigata, 9518520, Japan
Novartis Investigative Site
WITHDRAWN

Nijmegen, Gelderland, 6500HB, Netherlands
Novartis Investigative Site
COMPLETED

Leiden, South Holland, 2333 ZA, Netherlands
Novartis Investigative Site
WITHDRAWN

Barcelona, Catalonia, 08025, Spain
Novartis Investigative Site
WITHDRAWN

Port de Sagunt, Valencia, 46520, Spain
Novartis Investigative Site
WITHDRAWN

Barcelona, 08035, Spain
Novartis Investigative Site
COMPLETED

Madrid, 28041, Spain
Novartis Investigative Site
WITHDRAWN

Málaga, 29010, Spain
Novartis Investigative Site
COMPLETED

Seville, 41009, Spain
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Bern, 3010, Switzerland
Novartis Investigative Site
WITHDRAWN

Lausanne, 1011, Switzerland
Novartis Investigative Site
WITHDRAWN

Istanbul, Fatih, 34093, Turkey (Türkiye)
Novartis Investigative Site
WITHDRAWN

Istanbul, Fatih, 34098, Turkey (Türkiye)
Novartis Investigative Site
COMPLETED

Kayseri, Melikgazi, 38039, Turkey (Türkiye)
Novartis Investigative Site
COMPLETED

Ankara, Yenimahalle, 06500, Turkey (Türkiye)
Novartis Investigative Site
WITHDRAWN

Ankara, Yenimahalle, 06500, Turkey (Türkiye)
Novartis Investigative Site
WITHDRAWN

Glasgow, Scotland, G51 4TF, United Kingdom
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Newcastle upon Tyne, Tyne and Wear, NE1 4LP, United Kingdom
Novartis Investigative Site
COMPLETED

London, W12 0HS, United Kingdom
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

London, WC1N 3JH, United Kingdom
University of Iowa Health Care
RECRUITING

Iowa City, Iowa, 52242-1091, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Iowa Health Care
RECRUITING

Iowa City, Iowa, 52242, United States

Contact

Contact Phone: •••-•••-••••
University of Wisconsin
RECRUITING

Madison, Wisconsin, 53792, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

C3G